OSELTAMIVIR
(Tamiflu)Standard Prescription
oseltamivir__mg PO Q__H x__days
Dosages
Anti-viral treatment
Children:
< 12 months: 3 mg/kg/dose PO BID x 5 days
Dose interval and duration adjustment in renal impairment:
Children:
< 12 months: 3 mg/kg/dose PO BID x 5 days
>=12 months to <13 years: (weight based)
<= 15 kg: 30 mg/dose PO BID x 5 days
> 15 to 23 kg: 45 mg/dose PO BID x 5 days
> 23 to 40 kg: 60 mg/dose PO BID x 5 days
> 40 kg: 75 mg/dose PO BID x 5 days
Adolescents >= 13 years and adults:
75 mg/dose PO BID x 5 days
Patients with GFR <30 mL/min:
Once daily x 5 days
Patients on PD/HD:
Give single dose per above dosing, then consult pharmacist for post dialysis re-doseMechanism of Action
Antiviral; neuraminidase inhibitor
Forms Supplied
Capsule: 75 mg, 30 mg, 45 mg, 75mg
Suspension: 6 mg/mL (commercially available)
Suspension: 6 mg/mL (commercially available)
Comments
Indicated for patients who are moderately or severely ill with influenza-like illness or at high risk for influenza related complications (cardiac or pulmonary disorder, diabetes and other metabolic diseases, cancer, immunodeficiency/ immunosuppression, renal disease, anemia or hemoglobinopathy, children <2 years of age).
Refer to "BCCH oseltamivir algorithm" on PHSA SHOP
Greatest benefit is when oseltamivir is started within 48 hrs of influenza illness onset, but may still be beneficial when administered >48 hrs.
Pre-exposure and post-exposure prophylaxis is currently not recommended except in limited cases.
Dose adjustment required in patients with renal impairment (GFR <30 mL/min or dialysis).
Nausea and vomiting may be less severe if taken with food.
Transient neuropsychiatric events (self-injury, delirium) have been reported in postmarketing surveillance, with the majority in pediatric populations. Monitor for abnormal behaviors.
Capsules can be opened and mixed with sweetened liquids (chocolate syrup) or juice immediately prior to administration.
Refer to "BCCH oseltamivir algorithm" on PHSA SHOP
Greatest benefit is when oseltamivir is started within 48 hrs of influenza illness onset, but may still be beneficial when administered >48 hrs.
Pre-exposure and post-exposure prophylaxis is currently not recommended except in limited cases.
Dose adjustment required in patients with renal impairment (GFR <30 mL/min or dialysis).
Nausea and vomiting may be less severe if taken with food.
Transient neuropsychiatric events (self-injury, delirium) have been reported in postmarketing surveillance, with the majority in pediatric populations. Monitor for abnormal behaviors.
Capsules can be opened and mixed with sweetened liquids (chocolate syrup) or juice immediately prior to administration.
References
6, 44, 67, 112, 628
Last Edited
2022-07-28 01:15:50